0.97
0.97 (0%)
As of Feb 14, 2025
Engene Holdings Inc. [ENGNW]
Source:
Company Overview
Engene Holdings Inc. is a clinical-stage biotechnology company focused on developing genetic medicines to improve the lives of patients suffering from bladder cancer. We are developing non-viral genetic medicines based on our novel and proprietary dually derived chitosan, or “DDX”, gene delivery platform, which allows localized delivery of complex genetic cargos directly to mucosal tissues and other organs.
| Country | United States |
| Headquarters | saint-laurent |
| Phone Number | (514) 332-4888 |
| Industry | manufacturing |
| CEO | Ronald H. W. Cooper |
| Website | www.engene.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | |
| Operating Profit | $26.6 |
| Net Income | $24.6 |
| Net Cash | $-110.7 |
Profit Ratios
| Gross Margin | $0 |
| Operating Margin | |
| Profit as % of Revenues | |
| Profit as % of Assets | 8.3% |
| Profit as % of Stockholder Equity | 9.9% |
Management Effectiveness
| Return on Equity | 9.9% |
| Return on Assets | 8.6% |
| Turnover Ratio | |
| EBITA | $26.6 |
Balance Sheet and Cash Flow Measures
| Total Assets | $285.9 |
| Total Liabilities | $36 |
| Operating Cash Flow | $-25.7 |
| Investing Cash Flow | $-85 |
| Financing Cash Flow | $0 |
